174 related articles for article (PubMed ID: 38092014)
21. Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.
Zhong J; Sun W; Hu T; Wang C; Yan W; Luo Z; Liu X; Xu Y; Chen Y
Cancer Med; 2023 May; 12(10):11475-11482. PubMed ID: 37016119
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
Saiag P; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Dutriaux C
Eur J Cancer; 2021 Sep; 154():57-65. PubMed ID: 34243078
[TBL] [Abstract][Full Text] [Related]
23. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
[TBL] [Abstract][Full Text] [Related]
24. Targeted Therapy in Advanced Melanoma With Rare
Menzer C; Menzies AM; Carlino MS; Reijers I; Groen EJ; Eigentler T; de Groot JWB; van der Veldt AAM; Johnson DB; Meiss F; Schlaak M; Schilling B; Westgeest HM; Gutzmer R; Pföhler C; Meier F; Zimmer L; Suijkerbuijk KPM; Haalck T; Thoms KM; Herbschleb K; Leichsenring J; Menzer A; Kopp-Schneider A; Long GV; Kefford R; Enk A; Blank CU; Hassel JC
J Clin Oncol; 2019 Nov; 37(33):3142-3151. PubMed ID: 31580757
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
26. Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer.
Bazhenova L; Kish J; Cai B; Caro N; Feinberg B
Cancer Treat Res Commun; 2022; 33():100637. PubMed ID: 36162323
[TBL] [Abstract][Full Text] [Related]
27. Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: A retrospective, community oncology-based cohort study (A STROBE-compliant article).
Cowey CL; Liu FX; Boyd M; Aguilar KM; Krepler C
Medicine (Baltimore); 2019 Jul; 98(28):e16328. PubMed ID: 31305421
[TBL] [Abstract][Full Text] [Related]
28. Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study.
Liu X; Li JJ; Ding Y; Li DD; Wen XZ; Weng DS; Wang JH; Jiang H; Zhang XS
Front Oncol; 2021; 11():582676. PubMed ID: 33868987
[TBL] [Abstract][Full Text] [Related]
29. Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study.
Stege H; Haist M; Schultheis M; Fleischer MI; Mohr P; Meier F; Schadendorf D; Ugurel S; Livingstone E; Zimmer L; Herbst R; Pföhler C; Kähler K; Weichenthal M; Terheyden P; Nashan D; Debus D; Kaatz M; Ziller F; Haferkamp S; Forschner A; Leiter U; Kreuter A; Ulrich J; Kleemann J; Bradfisch F; Grabbe S; Loquai C
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065877
[TBL] [Abstract][Full Text] [Related]
30. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
31. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
32. Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer.
Betts KA; Gao S; Ray S; Schoenfeld AJ
Future Oncol; 2024 Apr; 20(13):851-862. PubMed ID: 38240151
[TBL] [Abstract][Full Text] [Related]
33. Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study.
Nadler E; Arondekar B; Aguilar KM; Zhou J; Chang J; Zhang X; Pawar V
J Cancer Res Clin Oncol; 2021 Mar; 147(3):671-690. PubMed ID: 33263865
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Advanced/Metastatic Melanoma in the United States and Western Europe: Results of the CancerMPact Survey.
Hawthorne S; Zhao L; Hanson M; Kanas G; Davis C; Robinson D; Turnure M; Clark O
Cancer Manag Res; 2020; 12():5633-5639. PubMed ID: 32765066
[TBL] [Abstract][Full Text] [Related]
35. Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective.
Stellato D; Gerbasi ME; Ndife B; Ghate SR; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Manag Care Spec Pharm; 2019 Nov; 25(11):1227-1237. PubMed ID: 31663466
[TBL] [Abstract][Full Text] [Related]
36. Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices.
Whitman ED; Liu FX; Cao X; Diede SJ; Haiderali A; Abernethy AP
Future Oncol; 2019 Feb; 15(5):459-471. PubMed ID: 30251550
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF
Czarnecka AM; Ostaszewski K; Borkowska A; Szumera-Ciećkiewicz A; Kozak K; Świtaj T; Rogala P; Kalinowska I; Koseła-Paterczyk H; Zaborowski K; Teterycz P; Tysarowski A; Makuła D; Rutkowski P
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008274
[TBL] [Abstract][Full Text] [Related]
38. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
39. Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer.
Danesi V; Massa I; Foca F; Delmonte A; Crinò L; Bronte G; Ragonesi M; Maltoni R; Manunta S; Cravero P; Andrikou K; Priano I; Balzi W; Gentili N; Burke T; Altini M
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139641
[TBL] [Abstract][Full Text] [Related]
40. Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients.
Rogala P; Czarnecka AM; Cybulska-Stopa B; Ostaszewski K; Piejko K; Ziętek M; Dziura R; Rutkowska E; Galus Ł; Kempa-Kamińska N; Seredyńska J; Bal W; Kozak K; Surus-Hyla A; Kubiatowski T; Kamińska-Winciorek G; Suwiński R; Mackiewicz J; Rutkowski P
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
